Feasibility Study, Number Of Lagoons

No definition available.

Name:	pfe_FeasibilityStudyNumberOfLagoons
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Class Actions Filed, Number

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyClassActionsFiledNumber
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Number Of Defendants Other Than Main Defendant

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Number Of Lawsuits

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyNumberOfLawsuits
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount awarded to other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of claims dismissed.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyClaimsDismissedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248

+ Details

Name:	us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number of another entity's patents that the entity has allegedly infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=pfe_InflectraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_HormoneTherapyProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_ClassActionVersusWyethMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_DocetaxelMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_ViolationofAntitrustLawsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_PhenytoinSodiumCapsulesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_EpiPenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Contingencies and Certain Commitments (Actions In Which We Are The Defendant) (Detail) £ in Millions, $ in Millions	1 Months Ended
	Mar. 29, 2020 USD ($) lawsuit	Oct. 31, 2018 manufacturer	Sep. 30, 2018 lagoon	Nov. 30, 2017 class_action	Mar. 31, 2015 Patents	Mar. 31, 2013 lagoon	Dec. 31, 2016 GBP (£)
Loss Contingencies [Line Items]
Number of class actions filed \| class_action				2
Inflectra [Member] \| Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon					6
Inflectra [Member] \| Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] \| Settled Litigation [Member]
Loss Contingencies [Line Items]
Claims dismissed					4
Inflectra [Member] \| Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] \| Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon					2
Hormone Therapy Products [Member] \| Class Action Versus Wyeth [Member] \| Settled Litigation [Member]
Loss Contingencies [Line Items]
Settlement agreed \| $	$ 200
Docetaxel [Member] \| Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member] \| Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of defendants other than main defendant \| manufacturer		8
Environmental Remediation Litigation [Member]
Loss Contingencies [Line Items]
Number of lagoons \| lagoon			2			2
Violation of Antitrust Laws [Member] \| Phenytoin Sodium Capsules [Member]
Loss Contingencies [Line Items]
Imposed fine \| £							£ 84.2
Minimum [Member] \| EpiPen [Member]
Loss Contingencies [Line Items]
Number of lawsuits \| lawsuit	1